Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...

U.S. Marketscategory Traders now see just one Fed rate cut this year February 7, 2025 U.S. Marketscategory US consumer sentiment drops as inflation expectations surge February 7, 2025 U.S ...